Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Medical and Pediatric Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9143391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.

  1996cited by this paper
• Biologic basis for interleukin-1 in disease.

  1996cited by this paper
• Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial.

  1994cited by this paper
• Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia.

  1994cited by this paper
• The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.

  1993cited by this paper
• Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice.

  1993cited by this paper
• Interleukin-1: therapeutic potential for solid tumors.

  1993cited by this paper
• Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

  1993cited by this paper
• Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.

  1992cited by this paper
• Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.

  1992cited by this paper
• Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine.

  1992cited by this paper
• Biology and clinical applications of hemopoietins in pediatric practice.

  1992cited by this paper
• The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

  1992cited by this paper
• Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.

  1991cited by this paper
• Common solid tumors of childhood.

  1991cited by this paper
• Interleukin-1 and interleukin-1 antagonism.

  1991cited by this paper
• A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.

  1991cited by this paper
• Clinical Effects of Recombinant Human Interleukin‐3

  1991cited by this paper
• Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.

  1990cited by this paper
• Problems in the investigational study and clinical use of cancer immunotherapy.

  1990cited by this paper
• Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1.

  1989cited by this paper
• A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cytokines in therapy of radiation injury.

  1988cited by this paper
• Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models.

  1988cited by this paper
• Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

  1988cited by this paper

• Osteosarcoma

  2019cites this paper
• A therapeutic perspective of cytokines in tumor management

  2014cites this paper
• Chapter 17 Cytokines and pain.

  2006cites this paper
• Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells.

  2002cites this paper
• Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients.

  2002cites this paper
• Altered Regulation of Cell Cycle Machinery Involved in Interleukin-1-induced G1 and G2 Phase Growth Arrest of A375S2 Human Melanoma Cells*

  2001cites this paper
• Phase I trial of a twice‐daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma

  2001cites this paper
• Comparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive Chemotherapy

  1998cites this paper